SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
نویسندگان
چکیده
* Department of Gastroenterology and Hepatology, AZ Groeninge Hospital, Kortrijk, Belgium. † Pôle Hépato-digestif, Unité Inserm U.1110, Université de Strasbourg, Laboratoire d’Excellence HepSys, Strasbourg, France. ‡ Southlake Regional Health Centre, Newmarket, ON, Canada. § Division of Gastroenterology, .Department of Medicine, NYU Langone Medical Center, New York University School of Medicine, New York, NY, USA. || Orlando Infectious Disease Center, Orlando, FL, USA. ¶ IST GmbH, Mannheim, Germany. ** F. Hoffmann-La Roche Ltd, Basel, Switzerland.
منابع مشابه
مقایسه پاسخ درمانی مداوم بیماران مبتلا به هپاتیت مزمن C با رژیم اینترفرون معمولی در مقابل پگیلیتد اینترفرون
Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...
متن کاملBalapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
INTRODUCTION Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. MATERIAL AND METHODS Treatment-naive genotype 1 patients (N = 516) were randomiz...
متن کاملAntiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
BACKGROUND & AIMS Danoprevir (RG7227; ITMN-191) is a potent inhibitor of the HCV NS3/4A serine protease. The aims of this double-blind, placebo-controlled, multiple-ascending dose phase Ib study were to evaluate safety, tolerability, antiviral activity, resistance, and pharmacokinetics of once- and twice-daily danoprevir in the presence of low-dose ritonavir (danoprevir/r) and in combination wi...
متن کاملSofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
BACKGROUND The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and efficacy of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-naive, patients with HCV. METHODS For this open-label, randomised phase 2 trial, we recruited patients from 42 centr...
متن کاملImpact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort
BACKGROUND Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of hepatology
دوره 13 2 شماره
صفحات -
تاریخ انتشار 2014